{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Status:
Possibly Marketed Outside US
Source:
NCT02639637: Phase 4 Interventional Completed Type 2 Diabetes Mellitus
(2015)
Source URL:
Class:
PROTEIN
Neuropeptide Y (NPY) is a 36 amino acid peptide neurotransmitter, which is widely expressed in the central and peripheral nervous systems of mammals. Neuropeptide Y has an important role in the stimulation of the appetite and is relevant to the pathophysiology of anxiety and depressionNeuropeptide Y is one of the most potent stimulators of feeding. At least five distinct G-protein coupled receptors (Y1, Y2, Y4, Y5, and Y6) mediate the actions of NPY. In rodents, repeated administration of Neuropeptide Y leads to hyperphagia and obesity associated with decreased thermogenesis in brown adipose tissue, hyperinsulinemia, hypercorticosteronaemia, reduced plasma testosterone concentrations, and insulin resistance in skeletal muscle. In the cardiovascular system Neuropeptide Y is found in neurons supplying the vasculature, cardiomyocytes, and endocardium, and is involved in physiological processes including vasoconstriction, cardiac remodeling, and angiogenesis. It is increasingly also implicated in cardiovascular disease pathogenesis, including hypertension, atherosclerosis, ischemia/infarction, arrhythmia, and heart failure. Neuropeptide Y is considered to be an anxiolytic endogenous peptide and its levels can be modulated by stress and it may also play a role in the etiology and pathophysiology of posttraumatic stress disorder.
Status:
Possibly Marketed Outside US
Class:
PROTEIN
Status:
Possibly Marketed Outside US
Source:
NCT02647554: Phase 4 Interventional Completed Sepsis
(2016)
Source URL:
Class:
PROTEIN
Status:
Possibly Marketed Outside US
Source:
NCT03576469: Phase 4 Interventional Completed CVI - Common Variable Immunodeficiency
(2018)
Source URL:
Class:
PROTEIN
Status:
Possibly Marketed Outside US
Source:
NCT00859079: Phase 4 Interventional Completed Diabetes Mellitus Type 2
(2006)
Source URL:
Class:
PROTEIN
Status:
Possibly Marketed Outside US
Class:
PROTEIN
Status:
Possibly Marketed Outside US
Source:
NCT04695483: Phase 4 Interventional Completed Infertility
(2022)
Source URL:
Class:
PROTEIN
Status:
Possibly Marketed Outside US
Source:
NCT04613284: Phase 4 Interventional Unknown status Lung Cancer
(2020)
Source URL:
Class:
PROTEIN
Status:
Possibly Marketed Outside US
Class:
PROTEIN
Status:
Possibly Marketed Outside US
Source:
NCT00720902: Phase 4 Interventional Terminated Growth Hormone Deficiency
(2007)
Source URL:
Class:
PROTEIN
Somatorelin is 29 amino acid analogue of human growth hormone-releasing hormone used as a diagnostic agent for determining growth hormone deficiency. Growth-hormone-releasing hormone (GHRH, somatoliberin) is the hypothalamic peptide hormone that specifically stimulates synthesis and release of growth hormone (GH, somatotropin) by somatotrope cells of the anterior pituitary gland. The hypothalamic hormone growth hormone (GH)-releasing hormone (GHRH) acts on specific GHRH receptors (GHRH-R) in the anterior pituitary gland to stimulate the synthesis and secretion of GH and to promote somatotrope expansion. Somatorelin is applied to determine the somatotropic function of the anterior pituitary gland in cases of suspected growth hormone deficiency. The test distinguishes between pituitary and hypothalamic disorders but is not suitable as a screening test for growth hormone deficiencies. Somatorelin has been used in trials studying the treatment of Aging, Elderly, Sleep Disorders, Hormone Deficiency, and Mild Cognitive Impairment.
